Adenovirus clinical trials at UCSF

• Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

  open to eligible people ages 1 month to 30 years

  Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

  San Francisco, California and other locations

Last updated: August 3, 2021